Toggle Health Problems and D

Far fewer vaccination antibodies against Omicron - Dec 14, 2021

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

Preprint https://doi.org/10.1101/2021.12.12.472269

Elisabetta Cameroni1*, Christian Saliba1*, John E. Bowen2*, Laura E. Rosen3*, Katja Culap1, Dora Pinto1, Anna De Marco1, Samantha K. Zepeda2, Julia di Iulio3, Fabrizia Zatta1, Hannah Kaiser3, Julia Noack3, Nisar Farhat3, Nadine Czudnochowski3, Colin Havenar-Daughton3, Kaitlin R. Sprouse2, Josh R. Dillen3, Abigail E. Powell3, Alex Chen3, Cyrus Maher 3, Li Yin3, David Sun3, Leah Soriaga3, Claes Gustafsson4, Nicholas M. Franko5, Jenni Logue5, Najeeha Talat Iqbal6, Ignacio Mazzitelli7, Jorge Geffner7, Renata Grifantini8, Helen Chu5, Andrea Gori9, Agostino Riva10, Olivier Giannini11,12, Alessandro Ceschi11,13,14,15, Paolo Ferrari11,16,17, Alessandra Franzetti-Pellanda18, Christian Garzoni19, Christy Hebner3, Lisa A. Purcell3, Luca Piccoli1, Matteo Samuele Pizzuto1, Alexandra C. Walls2,20, Amalio Telenti2, Herbert W. Virgin3,21,22,23, Antonio Lanzavecchia1,8,23, David Veesler2,20,23, Gyorgy Snell3,23, Davide Corti1,23
1Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland
2Department of Biochemistry, University of Washington, Seattle, WA 98195, USA
3Vir Biotechnology, San Francisco, California 94158, USA
4ATUM, Newark, California 94560, USA
5Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98195, USA.
6Department of Paediatrics and Child Health, Aga Khan University, Karachi, 74800, Pakistan
7Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, Buenos Aires
C1121ABG, Argentina
8National Institute of Molecular Genetics, Milano, Italy
9Infectious Disease Unit, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy 10Department of Biomedical and Clinical Sciences 'L.Sacco' (DIBIC), Università di Milano, Milan, Italy "Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland "
11Department of Medicine, Ente Ospedaliero Cantonale, Bellinzona, Switzerland 13Clinical Trial Unit, Ente Ospedaliero Cantonale, Lugano, Switzerland
12Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Science of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland
13Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland
"Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland
"Clinical School, University of New South Wales, Sydney, Australia
18Clinical Research Unit, Clinica Luganese Moncucco, 6900 Lugano, Switzerland.
19Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, 6900 Lugano, Switzerland. 20Howard Hughes Medical Institute, Seattle, WA 98195, USA.
21Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis MO 63110
22Department of Internal Medicine, UT Southwestern Medical Center, Dallas TX 75390
23These authors contributed equally: Herbert W. Virgin, Antonio Lanzavecchia, David Veesler, Gyorgy Snell and Davide Corti

The recently emerged SARS-CoV-2 Omicron variant harbors 37 amino acid substitutions in the spike (S) protein, 15 of which are in the receptor-binding domain (RBD), thereby raising concerns about the effectiveness of available vaccines and antibody therapeutics. Here, we show that the Omicron RBD binds to human ACE2 with enhanced affinity relative to the Wuhan-Hu-1 RBD and acquires binding to mouse ACE2. Severe reductions of plasma neutralizing activity were observed against Omicron compared to the ancestral pseudovirus for vaccinated and convalescent individuals. Most (26 out of 29) receptor-binding motif (RBM)-directed monoclonal antibodies (mAbs) lost in vitro neutralizing activity against Omicron, with only three mAbs, including the ACE2-mimicking S2K146 mAb1, retaining unaltered potency. Furthermore, a fraction of broadly neutralizing sarbecovirus mAbs recognizing antigenic sites outside the RBM, including sotrovimab2, S2X2593 and S2H974, neutralized Omicron. The magnitude of Omicron-mediated immune evasion and the acquisition of binding to mouse ACE2 mark a major SARS-CoV-2 mutational shift. Broadly neutralizing sarbecovirus mAbs recognizing epitopes conserved among SARS-CoV-2 variants and other sarbecoviruses may prove key to controlling the ongoing pandemic and future zoonotic spillovers.

 Download the PDF from VitaminDWiki

COVID-19 treated by Vitamin D - studies, reports, videos

As of May 16, 2022, the VitaminDWiki page had:  34 trials 10 trial results,   36 meta-analyses and reviews,   69 observations,   38 recommendations,   55 associations,  89 speculations,  58 videos, 45 Mortality studies   see related:   Governments,   HealthProblems,   Hospitals,  Dark Skins,   26 risk factors are ALL associated with low Vit D,   Recent Virus pages   Fight COVID-19 with 50K Vit D weekly   Vaccines   Take lots of Vitamin D at first signs of COVID


  • The above image is automatically updated

VItamin D appears to fight all variants of a wide number of viruses

VitaminDWiki pages with OMICRON in title

This list is automatically updated

Items found: 17

Created by admin. Last Modification: Tuesday December 28, 2021 01:59:59 GMT-0000 by admin. (Version 13)

Attached files

ID Name Comment Uploaded Size Downloads
16773 Anitbodies, vaccines, variants.jpg admin 20 Dec, 2021 11:12 102.26 Kb 232
16767 Anitbodies, vaccines, variants.jpg admin 17 Dec, 2021 00:57 133.48 Kb 194
16765 Effective vs variant_compressed.pdf PDF 2021 admin 17 Dec, 2021 00:38 3.26 Mb 120
See any problem with this page? Report it (WORKS NOV 2021)